ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
ARS Pharmaceuticals, a biopharmaceutical company focused on treatments for allergic reactions and anaphylaxis, announced a conference call and webcast on August 13, 2026, to outline updated strategic priorities and report their Q2 2026 financial results. The company is commercially offering neffy®, an epinephrine nasal spray approved for emergency …